Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation de l'efficacité et de l'innocuité du belantamab mafodotin, du bortézomib et de la dexaméthasone par rapport au daratumumab, au bortézomib et à la dexaméthasone chez les participants atteints de myélome multiple récidivant/réfractaire (DREAMM 7)

29 octobre 2026 mis à jour par: GlaxoSmithKline

DREAMM 7 : Une étude de phase III multicentrique, ouverte et randomisée pour évaluer l'efficacité et l'innocuité de l'association de belantamab mafodotin, bortézomib et dexaméthasone (B-Vd) par rapport à l'association de daratumumab, bortézomib et dexaméthasone (D-Vd ) chez les participants atteints de myélome multiple récidivant/réfractaire

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

494

Phase

  • Phase 3

Accès étendu

Approuvé en vente au public. Voir enregistrement d'accès étendu.

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Cologne, Allemagne, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Allemagne, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Allemagne, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Allemagne, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Allemagne, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Allemagne, 07747
        • GSK Investigational Site
    • New South Wales
      • Camperdown, New South Wales, Australie, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australie, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australie, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australie, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australie, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australie, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australie, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australie, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australie, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australie, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australie, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australie, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australie, 6009
        • GSK Investigational Site
      • Roeselare, Belgique, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Belgique, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Belgique, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgique, 9000
        • GSK Investigational Site
      • Joinville, Brésil, 89201-260
        • GSK Investigational Site
      • Natal, Brésil, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brésil, 22775001
        • GSK Investigational Site
      • São Paulo, Brésil, 04537-080
        • GSK Investigational Site
      • São Paulo, Brésil, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brésil, 88020-210
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H4J 1C5
        • GSK Investigational Site
      • Beijing, Chine, 100191
        • GSK Investigational Site
      • Beijing, Chine, 100020
        • GSK Investigational Site
      • Changchun, Chine, 130012
        • GSK Investigational Site
      • Guangzhou, Chine, 510060
        • GSK Investigational Site
      • Guangzhou, Chine, 510515
        • GSK Investigational Site
      • Hangzhou, Chine, 310003
        • GSK Investigational Site
      • Jinan, Chine, 250012
        • GSK Investigational Site
      • Nanjing, Chine, 210008
        • GSK Investigational Site
      • Shenyang, Chine, 110001
        • GSK Investigational Site
      • Suzhou, Chine, 215006
        • GSK Investigational Site
      • Tianjin, Chine, 300020
        • GSK Investigational Site
      • Zhengzhou, Chine, 450052
        • GSK Investigational Site
      • Pusan, Corée du Sud, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Corée du Sud, 13620
        • GSK Investigational Site
      • Seoul, Corée du Sud, 06351
        • GSK Investigational Site
      • Seoul, Corée du Sud, 06591
        • GSK Investigational Site
      • Ulsan, Corée du Sud, 44033
        • GSK Investigational Site
      • Barcelona, Espagne, 08035
        • GSK Investigational Site
      • Barcelona, Espagne, 08916
        • GSK Investigational Site
      • Cáceres, Espagne, 10003
        • GSK Investigational Site
      • Gijón, Espagne, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Espagne, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Espagne, 28933
        • GSK Investigational Site
      • Madrid, Espagne, 28007
        • GSK Investigational Site
      • Madrid, Espagne, 31008
        • GSK Investigational Site
      • Murcia, Espagne, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Espagne, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Espagne, 28223
        • GSK Investigational Site
      • Salamanca, Espagne, 37007
        • GSK Investigational Site
      • Amiens, France, 80054
        • GSK Investigational Site
      • Caen, France, 14033
        • GSK Investigational Site
      • Nice, France, 06200
        • GSK Investigational Site
      • Paris, France, 75651
        • GSK Investigational Site
      • Rennes, France, 35033
        • GSK Investigational Site
      • Athens, Grèce, 11528
        • GSK Investigational Site
      • Thessaloniki, Grèce, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Grèce, 681 00
        • GSK Investigational Site
      • Jerusalem, Israël, 91120
        • GSK Investigational Site
      • Kfar Saba, Israël, 44281
        • GSK Investigational Site
      • Ramat Gan, Israël, 52621
        • GSK Investigational Site
      • Tel Aviv, Israël, 64239
        • GSK Investigational Site
      • Bergamo, Italie, 24127
        • GSK Investigational Site
      • Bologna, Italie, 40138
        • GSK Investigational Site
      • Brescia, Italie, 25123
        • GSK Investigational Site
      • Catania, Italie, 95123
        • GSK Investigational Site
      • Meldola FC, Italie, 47014
        • GSK Investigational Site
      • Milan, Italie, 20133
        • GSK Investigational Site
      • Ravenna, Italie, 48121
        • GSK Investigational Site
      • Roma, Italie, 00168
        • GSK Investigational Site
      • Siena, Italie, 53100
        • GSK Investigational Site
      • Torino, Italie, 10126
        • GSK Investigational Site
      • Aichi, Japon, 467-8602
        • GSK Investigational Site
      • Aichi, Japon, 441-8570
        • GSK Investigational Site
      • Aomori, Japon, 030-8553
        • GSK Investigational Site
      • Ehime, Japon, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japon, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japon, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japon, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japon, 815-8555
        • GSK Investigational Site
      • Gifu, Japon, 503-8502
        • GSK Investigational Site
      • Gunma, Japon, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japon, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japon, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japon, 221-0855
        • GSK Investigational Site
      • Kochi, Japon, 781-8555
        • GSK Investigational Site
      • Nagano, Japon, 392-8510
        • GSK Investigational Site
      • Okayama, Japon, 701-1192
        • GSK Investigational Site
      • Osaka, Japon, 545-8586
        • GSK Investigational Site
      • Osaka, Japon, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japon, 411-8777
        • GSK Investigational Site
      • Christchurch, Nouvelle-Zélande, 8011
        • GSK Investigational Site
      • Dunedin, Nouvelle-Zélande, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Nouvelle-Zélande, 1309
        • GSK Investigational Site
      • Wellington, Nouvelle-Zélande, 6021
        • GSK Investigational Site
      • Groningen, Pays-Bas, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Pays-Bas, 3318 AT
        • GSK Investigational Site
      • Chorzów, Pologne, 41-500
        • GSK Investigational Site
      • Krakow, Pologne, 30510
        • GSK Investigational Site
      • Lodz, Pologne, 93-513
        • GSK Investigational Site
      • Lublin, Pologne, 20-081
        • GSK Investigational Site
      • Lublin, Pologne, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Pologne, 33-300
        • GSK Investigational Site
      • Poznan, Pologne, 60-569
        • GSK Investigational Site
      • Warsaw, Pologne, 02-781
        • GSK Investigational Site
      • Bournemouth, Royaume-Uni, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Royaume-Uni, CF14 4XW
        • GSK Investigational Site
      • Dundee, Royaume-Uni, DD1 9SY
        • GSK Investigational Site
      • Leicester, Royaume-Uni, LE1 5WW
        • GSK Investigational Site
      • London, Royaume-Uni, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Royaume-Uni, ST4 6QG
        • GSK Investigational Site
      • Sutton, Royaume-Uni, SM2 5PT
        • GSK Investigational Site
      • Moscow, Russie, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Russie, 603126
        • GSK Investigational Site
      • Novosibirsk, Russie, 630087
        • GSK Investigational Site
      • Saint Petersburg, Russie, 191024
        • GSK Investigational Site
      • Saint Petersburg, Russie, 197 089
        • GSK Investigational Site
      • Samara, Russie, 443021
        • GSK Investigational Site
      • Saratov, Russie, 410028
        • GSK Investigational Site
      • Ufa, Russie, 450083
        • GSK Investigational Site
      • Brno, Tchéquie, 625 00
        • GSK Investigational Site
      • Hradec Králové, Tchéquie, 500 05
        • GSK Investigational Site
      • Ostrava, Tchéquie, 708 52
        • GSK Investigational Site
      • Prague, Tchéquie, 128 08
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, États-Unis, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, États-Unis, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, États-Unis, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, États-Unis, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, États-Unis, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, États-Unis, 24014
        • GSK Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Belantamab mafodotin et bortézomib plus dexaméthasone (groupe A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Comparateur actif: Daratumumab et Bortézomib plus Dexaméthasone (Bras B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free Survival (PFS)
Délai: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Nombre de participants présentant des résultats oculaires anormaux à l'examen ophtalmologique
Délai: Jusqu'à 73 mois
Jusqu'à 73 mois
Complete Response Rate (CRR)
Délai: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Délai: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Délai: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Délai: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Délai: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Délai: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Délai: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Délai: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Délai: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Délai: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Délai: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Délai: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Délai: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Délai: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Délai: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Délai: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Délai: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Délai: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Délai: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Délai: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Délai: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: GSK Clinical Trials, GlaxoSmithKline

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 mai 2020

Achèvement primaire (Réel)

2 octobre 2023

Achèvement de l'étude (Estimé)

8 octobre 2029

Dates d'inscription aux études

Première soumission

27 janvier 2020

Première soumission répondant aux critères de contrôle qualité

27 janvier 2020

Première publication (Réel)

29 janvier 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner